Skip to content

Preoperative Glucose Infusion: a Novel Strategy to Improve Liver Function After Liver Resection

Metabolic Preconditioning Using Intravenous Dextrose: a Novel Strategy to Improve Hepatic Function After Liver Resection

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00623662
Enrollment
50
Registered
2008-02-26
Start date
2008-02-29
Completion date
2019-03-31
Last updated
2018-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic Insufficiency, Liver Failure

Keywords

Glucose infusion, Liver function, Liver resection, Albumin synthesis, Stable isotopes

Brief summary

The goal of the study is to determine whether intravenous glucose administration before liver resection preserves hepatic glycogen resulting in improved hepatic metabolic function after the operation. We further investigate whether the benefit of avoiding preoperative fasting is more pronounced in patients undergoing more extensive liver resection.

Detailed description

Background. With a reported incidence of up to 70%, liver failure is the most frequent complication necessitating intensive care and prolonging hospital stay. Animal studies suggest that the glycogen content of the liver is a key regulator of liver function and that glycogen depletion, a mandatory consequence of preoperative fasting, is associated with poor clinical outcome. The results of a pilot study demonstrate that metabolic preconditioning, i.e. the avoidance of preoperative fasting by intravenous administration of dextrose preserves hepatic glycogen and prevents hepatic dysfunction after liver resection. Liver function in this protocol was assessed by a score originally proposed by Schindl including serum concentrations of total bilirubin and lactate, prothrombin time and degree of encephalopathy. Due to alterations induced by anesthesia and surgery, e.g. blood loss necessitating transfusion, hypothermia, inflammatory responses and use of drugs with impact on hepatobiliary metabolism, liver function scores do not necessarily reflect functional integrity and metabolic capacity of the liver. In contrast, measuring the production of proteins that are exclusively synthetized by hepatocytes such as albumin allows a more specific and quantitative assessment of hepatic performance under perioperative conditions. Hypothesis. We propose a randomized double-blinded study to test the hypothesis that, in patients scheduled for resection of liver cancer, metabolic preconditioning with intravenous dextrose preserves hepatic glycogen resulting in improved hepatic metabolic function postoperatively. We further hypothesize that the benefit of avoiding preoperative fasting is more pronounced in patients undergoing more extensive liver resection. Hepatic synthetic capacity will be assessed by measuring albumin synthesis using a stable isotope tracer technique. Research plan. In order to test the validity of our assumptions, we will perform studies in patients scheduled for minor (study I; one or two liver segments, n=30) or major (study II; three or more liver segments, n=20) liver resection. In a double blinded fashion patients will be randomly assigned to receive either intravenous dextrose at 2 mg/kg/min or saline from 15:00 on the day before the operation until surgical skin incision. Metabolic processes at the organ level (liver, muscle), i.e. fractional synthesis rates of albumin, hepatic acute phase proteins (transthyretin (=prealbumin), fibrinogen, total plasma proteins) and muscle protein will be determined one day before and one day after the operation using primed-continuous infusions of L-\[2H5\]phenylalanine. Stable isotopes (L-\[1-13C\]leucine, \[6,6-2H2\]glucose) will be applied to assess dynamic changes in whole body protein and glucose metabolism before and after surgery, i.e. protein breakdown, amino acid oxidation, protein synthesis, glucose production and glucose uptake. Significance. The demonstration that the preconditioning with dextrose preserves metabolic performance of the liver would have important implications for the clinical management of surgical patients with liver cancer. If preoperative dextrose administration attenuates hepatic dysfunction after liver resection, it will provide these patients with a readily available, safe and inexpensive therapy.

Interventions

OTHERPreoperative glucose infusion

Glucose infusion from 15:00 on the day before the operation until beginning of surgery.

OTHERPreoperative normal saline infusion

Normal saline infusion from 15:00 on the day before surgery until beginning of the operation.

Sponsors

McGill University Health Centre/Research Institute of the McGill University Health Centre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* American Society of Anesthesiologists class ≤3 * liver resection (one or more liver segments) for primary or secondary malignancy * ability to give informed consent

Exclusion criteria

* signs of severe malnutrition or obesity: body mass index (BMI) \<20 or \>30 kg.m-2, more than 10% involuntary body weight loss over the preceding six months, serum albumin \<35 g.L-1 * chronic viral liver disease * diabetes mellitus * significant cardiorespiratory, renal and neurological disease * musculoskeletal or neuromuscular disease * severe anemia (hemoglobin \<10 g.dL-1) * history of severe sciatica or back surgery or other conditions which contraindicate the use of an epidural catheter

Design outcomes

Primary

MeasureTime frame
Rate of albumin synthesisOne day before and one day after surgery

Secondary

MeasureTime frame
Transthyretin synthesis, fibrinogen synthesis, whole body glucose and protein kineticsOne day before and one day after surgery

Countries

Canada

Contacts

Primary ContactRalph Lattermann, MD PhD
ralph.lattermann@muhc.mcgill.ca514-934-1934
Backup ContactThomas Schricker, MD PhD
thomas.schricker@mcgill.ca514-934-1934

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026